Peroxisome proliferator-activated receptor-γPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg Hypertension and Diabetes Project

Objective This study explored whether the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ (PPARγ) is associated with blood pressure in subjects with type 2 diabetes. Design A community-based, cross-sectional observation study. Setting Primary care. Patients One hundred and ninety-two men and 192 women with type 2 diabetes who consecutively underwent annual follow-up. Main outcome measure The PPARγPro12Ala genotype was determined by polymerase chain reaction-based techniques. Associations between genotype and blood pressure were analysed by linear regression and expressed as differences in blood pressure (Δ) with 95% confidence interval (CI). Results The mean systolic blood pressure and the diastolic blood pressure were 160 mmHg (standard deviation = 22.8) and 84 mmHg (standard deviation = 9.6), respectively. Subjects with Pro/Ala (24%) or Ala/Ala (2%) had lower diastolic blood pressure (Δ = 2.8; 95% CI, 0.6–5.0) when adjusted for age and gender compared with Pro/Pro subjects (74%). This association was restricted to men (Δ = 4.4; 95% CI, 1.3–7.4), who also had a borderline significant difference in systolic blood pressure (Δ = 6.9; 95% CI, –0.8 to 13.8). In men the difference in diastolic blood pressure remained after adjustment for age, body mass index, serum triglycerides, serum insulin and haemoglobin A1c (Δ = 4.6; 95% CI, 1.1–8.1). A subanalysis of normotensive men (n = 100) confirmed the difference associated with the Pro12Ala polymorphism in diastolic blood pressure (Δ = 5.2; 95% CI, 0.6–10.0). Conclusions The common Pro12Ala polymorphism in PPARγ is associated with lower diastolic blood pressure in male subjects with type 2 diabetes.

[1]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[2]  S. Haffner,et al.  The Homeostasis Model in the San Antonio Heart Study , 1997, Diabetes Care.

[3]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[4]  Q. Ren,et al.  Effect of the peroxisome proliferator-activated receptor-gamma 2 pro(12)ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. , 2001, The Journal of clinical endocrinology and metabolism.

[5]  J. Ranstam,et al.  Differences in treatment and metabolic abnormalities between normo- and hypertensive patients with type 2 diabetes: the Skaraborg Hypertension and Diabetes Project. , 1999, Diabetes, obesity & metabolism.

[6]  Eric S. Lander,et al.  The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes , 2000, Nature Genetics.

[7]  T. Kadowaki,et al.  The Pro12Ala Polymorphism in PPAR γ2 May Confer Resistance to Type 2 Diabetes , 2000 .

[8]  Julio E. Pérez,et al.  Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM , 1997, Diabetes.

[9]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[10]  J. Ranstam,et al.  Risk factor clustering in patients with hypertension and non‐insulin‐dependent diabetes mellitus. The Skaraborg Hypertension Project , 1998, Journal of internal medicine.

[11]  J. Beilby,et al.  A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. , 2001, European journal of endocrinology.

[12]  A. Sugawara,et al.  Transcriptional Suppression of Type 1 Angiotensin II Receptor Gene Expression by Peroxisome Proliferator-Activated Receptor-γ in Vascular Smooth Muscle Cells. , 2001, Endocrinology.

[13]  M. Kasuga,et al.  Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. , 2000, Biochemical and biophysical research communications.

[14]  V. Colantuoni,et al.  Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. , 1999, Diabetes.

[15]  F. Collins,et al.  The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. , 2001, Diabetes.

[16]  K. Takeda,et al.  Peroxisome Proliferator-Activated Receptor γ Activators Downregulate Angiotensin II Type 1 Receptor in Vascular Smooth Muscle Cells , 2000 .